Key players like Kinevant Sciences GmbH, aTyr Pharma, Inc., Novartis, and others hold the potential to create a significant positive shift in the Pulmonary Sarcoidosis market size.
DelveInsight’s “Pulmonary Sarcoidosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pulmonary Sarcoidosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Pulmonary Sarcoidosis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Pulmonary Sarcoidosis: An Overview
Sarcoidosis is an inflammatory disease characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organs of the body. Chronic inflammation can lead to fibrosis, the permanent scarring of organ tissue when left unchecked. Sarcoidosis in the lungs is called Pulmonary Sarcoidosis. The granulomas generally heal and disappear on their own. But, if they do not heal, the lung tissue can remain inflamed and become scarred and stiff. It changes the structure of the lungs and can affect breathing. The cause of pulmonary sarcoidosis is unknown. However, some studies show that bacteria, viruses, or chemicals might trigger the disease. It may also be genetic.
Pulmonary sarcoidosis can be complicated by fibrosis, which can be mild and clinically non-relevant but can also be progressive and life-threatening. Different patterns of fibrosis have been described from high-resolution CT (HRCT) scans, including bronchial distortion, linear pattern, and cystic lung disease, which can be accompanied by honeycombing.
Pulmonary Sarcoidosis Market Key Facts
In a study by Denning DW et al. (2013), published in European Respiratory Journal, out of total patients of Sarcoidosis, approximately 90% of patients have pulmonary sarcoidosis, which is characterized by the accumulation of granulomas, or small clusters of immune cells, in the lungs, potentially leading to enlarged lymph nodes, pulmonary hypertension, and fibrosis.
As per the study titled “Predictors of mortality in pulmonary sarcoidosis” conducted by Kirkil, G. et al. (2018), while most patients with sarcoidosis do well, increased mortality was seen in those patients who were older, had extensive fibrosis on high-resolution computer tomography, or pulmonary hypertension (PH).
In Japan, the prevalence of sarcoidosis is low and severer than in Western countries. According to an article by Terasaki et al. (2019), in Japan, the prevalence of sarcoidosis was estimated to range from 7.5 to 9.3 patients in 100,000.
Pulmonary Sarcoidosis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Pulmonary Sarcoidosis market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Pulmonary Sarcoidosis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Pulmonary Sarcoidosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Pulmonary Sarcoidosis Epidemiology, Segmented as –
Total Prevalent Cases of Sarcoidosis in the 7MM [2019–2032]
Diagnosed Prevalent Cases of Sarcoidosis in the 7MM [2019–2032]
Diagnosed Prevalent Cases of Pulmonary Sarcoidosis in the 7MM [2019–2032]
Treatable Cases of Pulmonary Sarcoidosis in the 7MM [2019–2032]
Pulmonary Sarcoidosis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Pulmonary Sarcoidosis market or expected to be launched during the study period. The analysis covers the Pulmonary Sarcoidosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pulmonary Sarcoidosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Pulmonary Sarcoidosis Market Will Evolve and Grow by 2032 @
Pulmonary Sarcoidosis Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Pulmonary Sarcoidosis. Currently, Corbus Pharmaceuticals is leading the therapeutics market with its Pulmonary Sarcoidosis drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Pulmonary Sarcoidosis Therapeutics Market Include:
And Many Others
Pulmonary Sarcoidosis Therapies Covered in the Report Include:
CMK 389: Novartis
ATYR1923: aTyr Pharma
RAYOS (Prednisone): Horizon Pharma USA, Inc.
Acthar Gel: Mallinckrodt Pharmaceuticals
Namilumab: Kinevant Sciences GmbH
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Pulmonary Sarcoidosis Competitive Intelligence Analysis
4. Pulmonary Sarcoidosis Market Overview at a Glance
5. Pulmonary Sarcoidosis Disease Background and Overview
6. Pulmonary Sarcoidosis Patient Journey
7. Pulmonary Sarcoidosis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Pulmonary Sarcoidosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Pulmonary Sarcoidosis Unmet Needs
10. Key Endpoints of Pulmonary Sarcoidosis Treatment
11. Pulmonary Sarcoidosis Marketed Products
12. Pulmonary Sarcoidosis Emerging Drugs and Latest Therapeutic Advances
13. Pulmonary Sarcoidosis Seven Major Market Analysis
14. Attribute Analysis
15. Pulmonary Sarcoidosis Market Outlook (In US, EU5, and Japan)
16. Pulmonary Sarcoidosis Access and Reimbursement Overview
17. KOL Views on the Pulmonary Sarcoidosis Market
18. Pulmonary Sarcoidosis Market Drivers
19. Pulmonary Sarcoidosis Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Services
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States